Multiple endocrine neoplasia type 2 laboratory findings: Difference between revisions
(Mahshid) |
|||
(9 intermediate revisions by 3 users not shown) | |||
Line 2: | Line 2: | ||
{{Multiple endocrine neoplasia type 2}} | {{Multiple endocrine neoplasia type 2}} | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
Laboratory findings consistent with the [[diagnosis]] of multiple endocrine neoplasia type 2 include [[hypercalcemia]], [[hypophosphatemia]], | Laboratory findings consistent with the [[diagnosis]] of multiple endocrine neoplasia type 2 include [[hypercalcemia]], [[hypophosphatemia]], [[Hyperparathyroidism|elevated parathyroid hormone]], and elevated [[norepinephrine]]. | ||
==Laboratory | |||
* | ==Laboratory Findings== | ||
* Laboratory findings consistent with the diagnosis of multiple endocrine neoplasia type 2 are tabulated below. | |||
{| style="border: 2px solid #B8B8B8; font-size: 90%; width: 30%;" | {| style="border: 2px solid #B8B8B8; font-size: 90%; width: 30%;" | ||
|+ '''Laboratory findings''' | |+ '''Laboratory findings''' | ||
|- | |- | ||
! style="width: 75px; background: #4479BA; text-align: center;"|{{fontcolor|#FFF|Test}} | ! style="width: 75px; background: #4479BA; text-align: center;" |{{fontcolor|#FFF|Test}} | ||
! style="width: 200px; background: #4479BA; text-align: center;"| {{fontcolor|#FFF|Findings}} | ! style="width: 200px; background: #4479BA; text-align: center;" | {{fontcolor|#FFF|Findings}} | ||
|- | |- | ||
| style="background: # | | style="background: #DCDCDC; padding: 5px; text-align: center;" | '''[[Metabolic]]''' | ||
| style="background: # | | style="background: #F5F5F5; padding: 5px;" | [[Hypophosphatemia]]<br>[[Hypercalcemia]]<br>Elevated [[calcitonin]]<br>Elevated [[epinephrine]]<br>Elevated [[norepinephrine]]<br>Elevated [[metanephrine]]<br>Elevated [[vanillylmandelic acid]]<br>Elevated [[parathyroid hormone]]<br>Elevated [[pentagastrin]] | ||
|- | |- | ||
| style="background: # | | style="background: #DCDCDC; padding: 5px; text-align: center;" | '''[[Urinalysis]]''' | ||
| style="background: # | | style="background: #F5F5F5; padding: 5px;" | Elevated [[norepinephrine]]<br>Elevated [[metanephrine]]<br>Elevated [[vanillylmandelic acid]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5; | | colspan="2" style="padding: 5px 5px; background: #F5F5F5;" |<small>Adapted from Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2015 Jun 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/<ref>{{Cite journal| author = [[Jessica Marquard]] & [[Charis Eng]] | ||
| title = Multiple Endocrine Neoplasia Type 2 | | title = Multiple Endocrine Neoplasia Type 2 | ||
| year = 1993 | | year = 1993 | ||
Line 25: | Line 27: | ||
}}</ref> | }}</ref> | ||
|} | |} | ||
<br> | |||
{| | {| | ||
|- | |- | ||
| valign=top | | | valign="top" | | ||
{|style="border: 0px; font-size: 90%; margin: 3px; width: 700px;" align=center | {| style="border: 0px; font-size: 90%; margin: 3px; width: 700px;" align="center" | ||
! style="padding: 0 5px; background: #4479BA" align=center |{{fontcolor|#FFF| Laboratory tests}} | ! style="padding: 0 5px; background: #4479BA" align="center" |{{fontcolor|#FFF| Laboratory tests}} | ||
! style="background:#4479BA;" align=center|{{fontcolor|#FFF| Normal Range}} | ! style="background:#4479BA;" align="center" |{{fontcolor|#FFF| Normal Range}} | ||
! style="background:#4479BA; width: 300px" align=center|{{fontcolor|#FFF| Abnormal value}} | ! style="background:#4479BA; width: 300px" align="center" |{{fontcolor|#FFF| Abnormal value}} | ||
|- | |- | ||
| style="padding: 0 5px; background: #4479BA" | | colspan="3" style="padding: 0 5px; background: #4479BA" |{{fontcolor|#FFF| Serum}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: # | ! style="padding: 0 5px; font-size: 100%; background: #DCDCDC" align="left" |Serum [[phosphate]] | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" | 2.4 to 4.1 mg/dL | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" | <2.4 or >4.1 | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: # | ! style="padding: 0 5px; font-size: 100%; background: #DCDCDC" align="left" |Serum [[calcium]] | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |8.5-10.2 mg/dL | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |<8.5 or >10.2 mg/dL | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: # | ! style="padding: 0 5px; font-size: 100%; background: #DCDCDC" align="left" |Serum [[calcitonin]] | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |less than 10pg/mL | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |>=100 pg/mL | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: # | ! style="padding: 0 5px; font-size: 100%; background: #DCDCDC" align="left" |Serum [[epinephrine]] | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |less than 30 pg/mL | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |> 30 pg/mL | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: # | ! style="padding: 0 5px; font-size: 100%; background: #DCDCDC" align="left" |Serum [[metanephrine]] | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |less than 30 pg/mL | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |> 30 pg/mL | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: # | ! style="padding: 0 5px; font-size: 100%; background: #DCDCDC" align="left" |Serum [[parathyroid hormone]] | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |10-65 pg/mL | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |<10 pg/mL or >65 pg/mL | ||
|- | |- | ||
| style="padding: 0 5px; background: #4479BA" | | colspan="3" style="padding: 0 5px; background: #4479BA" |{{fontcolor|#FFF| Urine}} | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: # | ! style="padding: 0 5px; font-size: 100%; background: #DCDCDC" align="left" |Epineprhine | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |0.5 - 20 mcg/24 hours | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |>20 mcg/24 hours | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: # | ! style="padding: 0 5px; font-size: 100%; background: #DCDCDC" align="left" |Metaneprhrine | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |24 - 96 mcg/24 hours | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |> 96 mcg/24 hours | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: # | ! style="padding: 0 5px; font-size: 100%; background: #DCDCDC" align="left" |[[Norepinephrine]] | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |15 - 80 mcg/24 hours | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |>80 mcg/24 hours | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: # | ! style="padding: 0 5px; font-size: 100%; background: #DCDCDC" align="left" |[[Normetanephrine]] | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |75 - 375 mcg/24 hours | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |>375 mcg/24 hours | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: # | ! style="padding: 0 5px; font-size: 100%; background: #DCDCDC" align="left" |Total urine [[catecholamine]]s | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |14 - 110 mcg/24 hours | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |>110 mcg/24 hours | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 100%; background: # | ! style="padding: 0 5px; font-size: 100%; background: #DCDCDC" align="left" |Total [[vanillylmandelic acid]] | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |2 - 7 milligrams (mg)/24 hours | ||
| style="padding: 0 5px; font-size: 100%; background: # | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align="left" |>7 milligrams (mg)/24 hours | ||
|} | |} | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Oncology]] | |||
[[Category:Diseases]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Up-To-Date]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
|} | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Surgery]] |
Latest revision as of 02:46, 27 November 2017
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 laboratory findings On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 laboratory findings |
FDA on Multiple endocrine neoplasia type 2 laboratory findings |
CDC on Multiple endocrine neoplasia type 2 laboratory findings |
Multiple endocrine neoplasia type 2 laboratory findings in the news |
Blogs on Multiple endocrine neoplasia type 2 laboratory findings |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Laboratory findings consistent with the diagnosis of multiple endocrine neoplasia type 2 include hypercalcemia, hypophosphatemia, elevated parathyroid hormone, and elevated norepinephrine.
Laboratory Findings
- Laboratory findings consistent with the diagnosis of multiple endocrine neoplasia type 2 are tabulated below.
Test | Findings |
---|---|
Metabolic | Hypophosphatemia Hypercalcemia Elevated calcitonin Elevated epinephrine Elevated norepinephrine Elevated metanephrine Elevated vanillylmandelic acid Elevated parathyroid hormone Elevated pentagastrin |
Urinalysis | Elevated norepinephrine Elevated metanephrine Elevated vanillylmandelic acid |
Adapted from Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2015 Jun 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/[1] |
References
|